Kalaris Therapeutics (KLRS) Net Cash Flow (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Net Cash Flow of -$63.6 million for Q1 2026, down 163.71% year-over-year from $99.9 million in Q1 2025, and down 214.36% quarter-over-quarter from $55.6 million in Q4 2025.
Kalaris Therapeutics (KLRS) Net Cash Flow (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$63.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 163.71% year-over-year to -$63.6 million; the TTM figure through Mar 2026 stood at -$31.9 million (down 121.1% YoY), while the FY2025 annual figure was $96.9 million, up 3.69% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$63.6 million, down from $55.6 million in the prior quarter.
- The five-year high for Net Cash Flow was $99.9 million in Q1 2025, with the low at -$101.5 million in Q1 2022.
- The 5-year median for Net Cash Flow is $4.7 million (2024), against an average of -$1.2 million.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow tumbled 321.03% in 2022, then soared 1084.75% in 2025.
- Kalaris Therapeutics' Net Cash Flow stood at -$17.7 million in 2022, then jumped by 68.97% to -$5.5 million in 2023, then surged by 185.29% to $4.7 million in 2024, then jumped by 1084.75% to $55.6 million in 2025, then sank by 214.36% to -$63.6 million in 2026.
- Business Quant data shows KLRS's Net Cash Flow at -$63.6 million in Q1 2026, $55.6 million in Q4 2025, and -$11.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | 8.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.77 Mn |
| Jun 30, 2026 | 8.77 Mn |
| Mar 31, 2026 | -63.63 Mn |
| Mar 31, 2026 | -63.63 Mn |
| Dec 31, 2025 | 55.64 Mn |
| Dec 31, 2025 | 55.64 Mn |
| Sep 30, 2025 | -11.31 Mn |
| Sep 30, 2025 | -11.31 Mn |
| Jun 30, 2025 | -12.60 Mn |
| Jun 30, 2025 | -12.60 Mn |
| Mar 31, 2025 | 99.87 Mn |
| Mar 31, 2025 | 99.87 Mn |
| Dec 31, 2024 | 4.70 Mn |
| Dec 31, 2024 | 4.70 Mn |
| Sep 30, 2024 | 15.68 Mn |
| Sep 30, 2024 | 15.68 Mn |
| Jun 30, 2024 | 30.98 Mn |
| Jun 30, 2024 | 30.98 Mn |
| Mar 31, 2024 | 42.08 Mn |
| Mar 31, 2024 | 42.08 Mn |